Literature DB >> 26822263

Examining the Role of Sphingosine Kinase-2 in the Regulation of Endothelial Cell Barrier Integrity.

David P Dimasi1, Stuart M Pitson1,2,3, Claudine S Bonder1,2,3.   

Abstract

OBJECTIVE: A key mediator of vascular EC barrier integrity, S1P, is derived from phosphorylation of sphingosine by the SK-1 and SK-2. While previous work indicates that SK-1 can regulate EC barrier integrity, whether SK-2 has a similar role remains to be determined.
METHODS: A cell impedance assay was used to assess human umbilical vein EC and bone marrow EC barrier integrity in vitro, with application of the SK inhibitors ABC294640, PF543, SKi, and MP-A08. In vivo studies were conducted using intravital microscopy to assess EC barrier integrity in SK-1 (Sphk1(-/-)) and SK-2 (Sphk2(-/-)) knock-out mice.
RESULTS: Only ABC294640 and MP-A08, which can both inhibit SK-2, caused a decrease in EC barrier integrity in vitro in both cell types. Intravital microscopy revealed that Sphk1(-/-) mice had reduced EC barrier integrity compared to WT mice, whereas no change was evident in Sphk2(-/-) mice.
CONCLUSIONS: Our data suggest that in vitro inhibition of SK-2, can compromise the integrity of the EC monolayer, while SK-1 exerts a more dominant control in vivo. These data may have clinical implications and could aid in the development of new treatments for disorders of vascular barrier function.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  endothelial cell barrier integrity; sphingosine kinase; sphingosine-1-phosphate

Mesh:

Substances:

Year:  2016        PMID: 26822263     DOI: 10.1111/micc.12271

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  5 in total

1.  Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.

Authors:  Elizabeth S Childress; Yugesh Kharel; Anne M Brown; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  J Med Chem       Date:  2017-04-25       Impact factor: 7.446

Review 2.  Sphingolipids in spinal cord injury.

Authors:  Zachary B Jones; Yi Ren
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-08-05

Review 3.  Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.

Authors:  Diana Hatoum; Nahal Haddadi; Yiguang Lin; Najah T Nassif; Eileen M McGowan
Journal:  Oncotarget       Date:  2017-05-30

Review 4.  Barrier maintenance by S1P during inflammation and sepsis.

Authors:  Anke C Ziegler; Markus H Gräler
Journal:  Tissue Barriers       Date:  2021-06-21

Review 5.  Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.

Authors:  Eileen M McGowan; Nahal Haddadi; Najah T Nassif; Yiguang Lin
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.